94,816 Shares in Bristol Myers Squibb Company $BMY Purchased by Global Retirement Partners LLC

Global Retirement Partners LLC bought a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 94,816 shares of the biopharmaceutical company's stock, valued at approximately $5,463,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Norges Bank bought a new stake in shares of Bristol Myers Squibb during the fourth quarter valued at approximately $1,947,272,000. AQR Capital Management LLC grew its holdings in Bristol Myers Squibb by 172.6% in the 4th quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company's stock worth $1,391,485,000 after buying an additional 16,332,924 shares in the last quarter. Bank of New York Mellon Corp increased its position in Bristol Myers Squibb by 47.0% in the 4th quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company's stock valued at $1,321,308,000 after acquiring an additional 7,837,485 shares during the period. Geode Capital Management LLC increased its position in Bristol Myers Squibb by 13.1% in the 4th quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company's stock valued at $2,837,026,000 after acquiring an additional 6,084,046 shares during the period. Finally, Man Group plc raised its stake in Bristol Myers Squibb by 280.4% during the 2nd quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company's stock valued at $345,594,000 after acquiring an additional 5,503,391 shares in the last quarter. Institutional investors own 76.41% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on BMY. Roth Capital started coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a "buy" rating and a $75.00 price target for the company. Royal Bank Of Canada lifted their price objective on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a "sector perform" rating in a research note on Friday, July 31st. Sanford C. Bernstein raised shares of Bristol Myers Squibb from a "market perform" rating to an "outperform" rating in a report on Wednesday, August 5th. Wall Street Zen upgraded shares of Bristol Myers Squibb from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 27th. Finally, Raymond James Financial initiated coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a "strong-buy" rating on the stock. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $66.06.

Bristol Myers Squibb Price Performance

Shares of Bristol Myers Squibb stock opened at $64.71 on Tuesday. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $68.10. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89. The stock has a market cap of $132.18 billion, a PE ratio of 14.25, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22. The company's 50-day moving average price is $59.75 and its two-hundred day moving average price is $59.06.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.44. The company had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The business's revenue for the quarter was up 5.7% on a year-over-year basis. During the same quarter last year, the firm posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. As a group, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 3.9%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb's dividend payout ratio (DPR) is presently 55.51%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source